✦ LIBER ✦

Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells

✍ Scribed by Kiyotaka Kawauchi; Toshie Ogasawara; Masako Yasuyama; Shin-ichiro Ohkawa

Book ID: 117726524
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 330 KB
Volume: 31
Category: Article
ISSN: 1079-9796
DOI: 10.1016/s1079-9796(03)00070-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reversal of the resistance to STI571 in

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

✍ Motoi Mukai; Xiao-Fang Che; Tatsuhiko Furukawa; Tomoyuki Sumizawa; Shunji Aoki; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

The effects of STI571 on antigen present

The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia

✍ Naoko Sato; Miwako Narita; Masuhiro Takahashi; Kumiko Yagisawa; Aichun Liu; Taka 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 1 views

## Abstract Chronic myelogenous leukemia is caused by the acquisition of the reciprocal (9;22)(q34;q11) chromosomal translocation in hematopoietic stem cells. The fusion protein showed higher and aberrant tyrosine kinase activity. The inhibition of the tyrosine kinase activity of the protein repres

In vitro effects of STI 571-containing d

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

✍ Barbara Scappini; Francesco Onida; Hagop M. Kantarjian; Li Dong; Srdan Verstovse 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 607 KB

## Abstract ## BACKGROUND Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion __BCR‐ABL__ gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR‐ABL protein tyrosine kinase activity by a tyro

Synergistic activity of the new ABL-spec

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

✍ Topaly, J; Zeller, W J; Fruehauf, S 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 138 KB

STI571, a tyrosine kinase inhibitor for

STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

✍ Michael J. Mauro; Michael E. O'Dwyer; Brian J. Druker 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 66 KB

Phosphoinositide 3-kinase/Akt involvemen

Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells

✍ Giovanna Tabellini; Alessandra Cappellini; Pier Luigi Tazzari; Federica Falà; An 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB

## Abstract The purpose of this study was to evaluate the possible involvement of the phosphoinositide 3‐kinase (PI3K)/Akt survival pathway in determining resistance to arsenic trioxide (As~2~O~3~)‐induced apoptosis. We employed a HL60 cell clone (HL60AR) with a constitutively active PI3K/Akt survi